Jason Weil

I'll research this attorney before drafting.

Let me verify the tracked case and check for any additional context.

Jason Weil — Patent Litigation Practice Summary

Specialty / focus. Weil is a patent litigator with a life-sciences and technology emphasis. Akin's own profile describes his technical range as monoclonal antibody therapies, biosimilars, DNA diagnostics, and medical devices, and lists SEP/FRAND disputes and IP appellate work among his areas of focus. His practice includes district court patent litigation, PTAB proceedings, and BPCIA/biosimilar matters; his publications in recent years span both life-sciences issues (written description, antibody-drug conjugates) and general patent doctrine (collateral estoppel, IPR estoppel, damages/marking). His Ph.D. in biology (Johns Hopkins) underlies the biotech concentration.

Side preference. The tracked data shows one plaintiff-side and one defendant-side appearance — both in the Wound Healing Technologies Corp. v. Solventum dispute — so the sample is too thin to support a firm-side characterization. Publicly verifiable work skews toward operating companies: Akin represented Solventum as defendant/petitioner in Wound Healing Technologies Corp. v. Solventum Corp. (W.D. Tex. No. 6:24-cv-589; IPR2025-01042) and Boston Scientific as plaintiff in Boston Scientific Corp. v. Nevro Corp., where he also worked the parallel IPRs. I could not verify any NPE/PAE-side representation. Note the same party name appears on both sides of the tracked list; that likely reflects separate docket or related-proceeding records rather than two distinct clients, and should be confirmed against the source docket.

Firm context. Weil has been at Akin Gump Strauss Hauer & Feld throughout his post-clerkship career (Philadelphia office), where he is listed as senior counsel and is a regular contributor to the firm's IP Newsflash blog and Law360. No prior firm appears in searched sources; he clerked for Judge Richard Linn of the U.S. Court of Appeals for the Federal Circuit before joining Akin. (Martindale lists him as "partner," which conflicts with Akin's own "senior counsel" designation.)

Notable matters and outcomes. The most prominent verified result is Boston Scientific Corp. v. Nevro Corp. (D. Del.), where a Delaware jury returned a $20 million willful-infringement verdict for Boston Scientific in October 2021; Weil is named on the Akin trial team. He also handled the related Boston Scientific IPRs, including filing Sotera-style stipulations in IPR2020-01562 and IPR2020-01563 and appearing on IPR2021-00295. On the patent-owner side, Akin's profile credits him with defeating institution of three IPRs challenging Cornell University's DNA detection patents, and with defeating institution of a dental-materials IPR for a large corporation. In the tracked Wound Healing matter, Solventum's IPR petition against U.S. Patent No. 10,639,404 was instituted (IPR2025-01042) while the district court case was stayed.

PTAB / IPR experience. Yes — Weil appears regularly in PTAB matters as counsel (petitioner and patent-owner side) and writes frequently on IPR practice, including discretionary denial, Fintiv/Sotera stipulations, and IPR estoppel.

Bar / education. Admitted in Pennsylvania (2011) and registered with the USPTO (Reg. No. 73,132); J.D., George Washington University Law School (highest honors, 2011); Ph.D., Johns Hopkins (2008); B.S., Rochester Institute of Technology (2001).